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Abstract
The clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the
treatment of inflammatory bowel diseases (IBD). It has demonstrated impressive efficacy as
compared to alternative treatments, allowing for the chance to achieve near-remission and
long-term improvement in function and quality of life and to alter the natural history of Crohn's
disease (CD) and ulcerative colitis (UC). As a consequence of longer follow-up periods the
number of side effects which may be attributed to treatment with biologics is growing
significantly. Cutaneous reactions are among the most common adverse reactions. These
complications include injection site reactions, cutaneous infections, immune-mediated
complications such as psoriasis and lupus-like syndrome and rarely skin cancers. We review the
recent literature and draw attention to dermatological side effects of anti-TNF therapy of
inflammatory bowel disease.
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TNF is a pro-inflammatory cytokine implicated in the patho-
genesis of chronic inflammatory diseases such as IBD, CD and
UC as well as rheumatologic and dermatological diseases such
as rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic
arthritis, and psoriasis. During the last two decades, TNF
antagonists, including infliximab (a chimeric monoclonal anti-
tumour necrosis factor antibody), adalimumab (human mono-
clonal antibody), certolizumab (the Fab fraction of human IgG
monoclonal antibody) and etanercept (a soluble receptor
fusion protein), were developed and have been used world-
wide to treat more than 2 million patients affected by
various autoimmune and idiopathic inflammatory diseases.1,2
Anti-TNF agents are generally well tolerated, even if they are
not free of side effects. The main side effects include serious
infections, malignancies, demyelinating disease, aplastic
anaemia, congestive heart failure, and induction of autoim-
mune conditions.3 The use of TNF blockers may also provoke a
broad spectrum of dermatological side effects, including
injection site reactions, cutaneous manifestations of infusion
reactions, cutaneous infections, non-melanoma skin cancer
(NMSC), and psoriasis. Other cutaneous side effects are rare
lesions including lupus-like syndrome, Stevens–Johnson syn-
drome (SJS), erythema multiforme (EM), and toxic epidermal
necrolysis (TEN).4,5 Different factors can be responsible for the
immunogenicity of the anti-TNF agents. The degree of
humanization, the content of adjuvants, the IgE or not IgE
mediated immune responses can cause acute or delayedTable 1 Anti-TNF and IBD: skin manifestations.
• Injection site reactions.
• Infusion reactions.
• Infectious complications
○ Bacterial cellulitis, erysipelas, abscess
○ HSV, VZV, CMV, HPV, MC
○ Candida species
• Immune-mediated and toxic complications:
○ Psoriasis
○ Cutaneous lupus
○ Lupus like-syndrome
○ Cutaneous vasculitis
○ Erythema multiforme
○ Stevens Johnson syndrome
○ Toxic epidermal necrolysis
• Skin cancers:
○ Melanoma
○ Non-melanoma skin cancer
▪ Basal cell carcinoma
▪ Squamous cell carcinomareactions (local or systemic urticaria, erythema, local
dermatitis, serum sickness). A deregulated TNF production has
also been associated with autoimmunity and autoinflammatory
disorders such as psoriasis or lupus-like syndrome.6 Rheumato-
logic studies have demonstrated that almost 25% of patients
undergoing anti-TNF therapy had a dermatological complica-
tion,7,8 and more recently, these data have also been
confirmed in IBD cohorts.9,10 In this clinical review, we focused
on the most frequent dermatologic complications. We also
examined the clinical management of the different dermato-
logical situations induced by TNF antagonist therapy (Table 1).2. Reactions to injection/infusion
Injection site reactions occur with the use of adalimumab,
etanercept and certolizumab pegol. These reactions mani-
fest as redness, itching, bruising, pain, swelling and/or
irritation at the site of injection. An allergic hypersensitivity
reaction and local trauma are the most important mecha-
nisms for injection reactions. Usually, clinical presentation
is mild and occurs in the first months. Reactions typically
last for 3–5 days, subsequently disappear11 (Fig. 1). Injec-
tion site reaction based on an allergic mechanism may later
present as systemic allergic reaction when treatment is
continued. Food and Drugs Administration (FDA) labels for
TNF inhibitors demonstrate that these local reactions
occurred more often in TNF treated patients compared to
those treated with placebo. Further, the incidence of such
local reactions is up to 20% in adalimumab-treated patients
compared to 14% in the placebo group and up to 37% in
etanercept-treated patients compared to 10% in patients
receiving placebo.11 The higher number of injection site
reactions with etanercept compared to adalimumab are
likely due to more frequent dosing, longer availability on the
market, and because it is a larger treatment group, as this
drug has been available for longer than other agents.
Injection site reactions are generally well tolerated and
should be treated with supportive and preventive measures
such as cool packs with a temperature around 4 °C, topical
corticosteroids, rotation of injection sites and pain control if
necessary. However, very few patients require discontinua-
tion of TNF inhibitors.
Infusion reactions occur with infliximab (IFX) and are
classified as acute or delayed, both of which can have
cutaneous manifestations.4,12 Acute reactions to IFX are
infusion-related reactions that occur during or within 1 h
after infusion.10,13,14 These reactions appear in 10–40% of
IFX-treated patients and include urticaria, erythematous rash,
fever, bronchospasm, laryngopharyngeal oedema, dyspnoea,
and hypotension.4,10,11,13,14 Pruritus, flushing and urticaria
are the most common symptoms and are observed in up to
2.2% of these patients compared to 0.3% of controls.15 Acute
reactions to IFX can be further categorised as mild-moderate,
Figure 1 Injection site reaction with the use of adalimumab.
Table 2 Acute and delayed reactions under infliximab
therapy.
No. of
patients
Acute Delayed IBD
Hanauer 200225 573 97 (17%) CD
Cheifetz 200318 165 14 (8.5%) 3 (1.8%) CD
Colombel 200422 500 19 (3.8%) 14 (2.8%) CD
Rutgeerts 200526 484 55 (11%) 3 (0.6%) UC
Moss 200827 287 52 (18%) – CD
Lees 200921 202 19 (9.4%) 8 (3.9%) CD and UC
Fidder 200910 682 115 (17%) 50 (7%) CD and UC
Ducharme
201017
2036 158 (8%) CD and UC
Steenholdt
201112
315 8 (2.5%) – CD and UC
771Anti-TNF and IBD: dermatological manifestationswhich may be associated with nausea, fever, itching erythema
and/or mild wheal formation, and severe, which may present
with fever, generalized urticaria, angioedema, chest discom-
fort, dyspnoea, hypotension, and allergic shock.12–14,16,17 The
management of these types of reactions is different. Mild to
moderate reactions in the most cases are self-limited and
simply require slowing the infusion rate or a temporary
interruption of the infusion. They may however be the first
manifestations of hypersensitivity against the compound, with
worsening with every infusion. However, acute severe infusion
reactions constitute a serious clinical problem requiring
immediate patient stabilisation and vital sign monitoring,
discontinuation of the infusion and consequent indefinite
contraindication to IFX therapy.14,17 Furthermore, practice
guidelines recommend premedication with anti-histamines
and acetaminophen to reduce the incidence and severity of
acute infusion reactions.18–20 Interestingly, some authors
investigating potential risk factors associated with acute
severe infusion reactions have observed that the risk of
reaction is higher during episodic or re-initiation therapy,
especially during the 2nd infusion in a new series,11 whereas
the risk decreased with concomitant use of immunosuppres-
sive therapy.10,15,21,22 However, the risk of these reactions in
two rheumatologic cohorts was not reduced by pre-treatment
with systemic betamethasone or diphenhydramine.23,24
Finally, delayed infusion reactions are serum sickness-like
reactions that occur 1–14 days after infusion. They typically
manifest as myalgias, arthralgias, headache, fever, facial
oedema, rash and fatigue.12–14 FDA data and post-marketing
reviews show an overall occurrence rate of about 2% of those
patients treated with IFX.10,12–14,21
Table 2 shows pooled data for the incidence of acute and
delayed infusion reactions with IFX in IBD from various
registers and reviews.
Mechanisms for infusion reactions include immune and
non-immune-mediated pathways. It is hypothesised that
these reactions are caused by IFX immunogenicity.14,16 In
the ACCENT I trial, 42/254 infusions (16%) were given to
anti-IFX antibody-positive patients compared with 55/656
(8%) given to anti-IFX antibody-negative patients.25 Higher
antibody titres were not associated with more infusion
reactions in ACCENT I,28 even though other studies reported
that concentrations of 8 mcg/ml or higher predicted ahigher risk for infusion reaction (relative risk 2.4).29 In
order to evaluate the role of immunogenicity in acute severe
reactions systematically, a Danish group measured anti-IFX
IgG and IgE antibodies levels in 25 IBD patients after these
reactions.12 Surprisingly, the authors found a clear associa-
tion between these reactions and the presence of high levels
of circulating anti-IFX IgG antibodies, but not with the
presence of anti-IFX IgE antibodies. They thus concluded
that most acute severe infusion reactions to IFX are not true
anaphylactic reactions. Moreover, by measuring the levels of
these antibodies before re-initiation of IFX infusion after a
period of drug discontinuation, the same authors demon-
strated that patients negative for anti-IFX antibodies before
re-initiation still had infusion reactions.
3. Infectious complications
It has become clear from both randomised controlled trials
(RCTs) and post-marketing surveillance that patients with
rheumatoid arthritis treated with anti-TNF agents are at
increased risk of bacterial, viral, fungal and opportunistic
infections of all aetiologies.30–37 Data are less robust in IBD
patients because the pivotal trials on biological therapy in
this population have not demonstrated an increased risk of
serious infections.38–40 Alternatively, cohort studies from
several centres suggest that the risk for serious cutaneous
infections is increased significantly.22 In terms of skin
infections, particularly in the subgroup of serious cutaneous
infections defined as those that result in new or prolonged
hospitalisation or are life-threatening, permanently dis-
abling, or fatal, the precise incidence is not fully known.
At present, there are only a few data from rheumatological
cohorts showing an incidence of cutaneous infections and
serious cutaneous infections of about 7–8% and 1.5%,
respectively.32,41,42 Data from the British Society for
Rheumatology Biologics Register (BSRBR, a registry of 9018
patients, 7664 treated with adalimumab, etanercept and
IFX) and the German register (1529 patients of whom 858
have had therapy with IFX or etanercept) follow-up the use
of biologics in RA. The data of these cohorts have confirmed
772 G. Mocci et al.that the skin is the second most common site of serious
infections after infections of the respiratory tract.42–44
Many risk factors have been identified as causes of
increased cutaneous infections during anti-TNF therapy,
including a dose increase, concomitant immunosuppressive
therapy, malnutrition, age, and comorbidities such as chronic
lung disease, alcoholism, organic brain disease and diabetes
mellitus.45–47 The rheumatologic literature has demonstrated
that each immunomodulator carries an increased risk of
infection, and combinations of immunosuppressive therapy
are associatedwith an incremental increase in the relative risk
of opportunistic infections.48 For patients under corticoste-
roids, the relative risk of occurrence of infectious complica-
tions is 1.6. The overall risk of infection increases for doses of
Prednisolone N10 mg/day or cumulative doses N700 mg.
Moreover, a duration of steroid therapy N2 weeks predisposes
patients to infections.47–50
Cutaneous bacterial infections include cellulitis, erysipe-
las, abscess formation and pharyngitis and occur in less than
0.1% to 7% of anti-TNF treated patients.7,10,15,22,32 Fungal
infections (Candida species) are more commonly associated
with corticosteroid and anti-TNF therapy, but the exact
incidence of cutaneous fungal infections is unknown.7,8,32,48
With regard to viral infections, TNF is involved in the
regulation of herpes virus replication and dissemination.51
Reactivation of herpes virus infection in patients undergoing
anti-TNF therapy is relatively common, with an incidence of
1–5% in the various registers and reviews.7,10,32 In particu-
lar, shingles (Herpes zoster), a neurocutaneous disease
typically characterised by a painful, unilateral, vesicular
rash distributed in one or more dermatomes, is the result
of reactivation of the varicella zoster virus (VZV). VZV
reactivation is well documented in patients receiving anti-
TNF therapy, with an incidence of about 3%, and appears to be
particularly associated with IFX and adalimumab thera-
pies.52,53 Concomitant immunosuppressive therapy increases
the risk of dissemination and complications such as bacterial
superinfection, post-herpetic neuralgia, thrombocytopenia
and disseminated intravascular coagulopathy.54 In the Euro-
pean Crohn's and Colitis Organisation (ECCO) Consensus on the
prevention, diagnosis and management of infections in IBD
patients, experts concluded that previous VZV infection is not
a contraindication to immunomodulator therapy but that
biologics should not be started during an active infection. A
serologic test for chickenpox and VZV infection should be
recommended in order to assess immunologic status of a
patient and to decide if vaccination is necessary or not:
vaccination should be performed at least 3 weeks before the
onset of immunomodulator therapy. In the case of VZV
infection during immunomodulator therapy, antiviral treat-
ment should be started, and immunomodulator and/or
anti-TNF therapy should be discontinued if possible. Finally,
anti-TNF therapy can be safely restarted after complete
clearance of lesions.46
There are also reported cases of CMV infections that may
present as cutaneous ulcers or retinitis.55
Recently, few case reports of human papilloma virus
(HPV) and molluscum contagiosum (MC) infection in patients
under anti-TNF treatment for psoriasis, were reported.56,57
One case of genital condylomata in a patient receiving IFX
for CD was described.58 HPV and MC viral proteins seem to
interfere with the apoptotic pathway of the host cell signalledby TNF receptors. Anti-TNF agents block TNF directly, so HPV
and MC could develop or flare. For females, PAP smear test
before and during anti-TNF therapy is highly recommended.594. Immune-mediated complications
4.1. Psoriasis
TNF inhibition is effective and approved for the treatment of
moderate to severe psoriasis.60,61 However, as experiencewith
the use of biological therapeutic is increasing, a significant
number of cases of psoriasis induced by anti-TNF therapy
have been reported.62 This paradoxical side effect has been
described in nearly all conditions treated with anti-TNF and
with all anti-TNF agents. In a series of 127 patients treatedwith
biologic agents for a number of primary autoimmune conditions
(70 on IFX, 35 on etanercept, and 22 on adalimumab), authors
have reported a prevalence of new-onset psoriasis ranging
from 0.6% to 5.3%.63 The majority of these cases have been
described in rheumatologic diseases, but this side effect has
also been described in IBD patients.64,65 New-onset psoriasis
during treatment with TNF blockers is not rare: 15% of all cases
are RA patients.66,67 The prevalence of psoriasis is greater in CD
than in UC.68–70 Moreover, a great majority of cases have been
described after IFX therapy, perhaps due to the fact that IFX
was the first anti-TNF agent used for the treatment of IBD,
whereas adalimumab is a far more recent addition to the
therapeutic arsenal for the treatment of CD.66–88
The pathogenic mechanism of this paradox reaction has
not yet been completely clarified. A possible aetiology might
be the balance between TNF and interferon-α (IFNα), an
important cytokine for the early phase of induction of
psoriasis produced by the dermal plasmocytoid dendritic
cells (DPDC). According to this hypothesis, TNF can inhibit
the release of IFNα by DPDC; therefore, TNF blockade may
induce a local uncontrolled and unlimited production of IFNα
that may cause the onset of psoriatic lesions. However,
because only few patients on anti-TNF therapy develop
psoriasis, a genetic predisposition is likely.86–90
Cullen et al., in a recent work, identified 30 subjects who
developed a psoriatic rash while receiving anti-TNF therapy
for IBD and combined these new data with those from 120
published cases of anti-TNF-induced psoriasis in IBD. In this
analysis, anti-TNF-induced psoriasis in IBD seems to be more
common in women (70%).91
Denadai et al. published a review, including 47 studies,
that documented 222 cases of IBD patients with psoriasis
induced or exacerbated by anti-TNF. Of the 222 patients,
78% were affected by CD, 48% were female. IFX was the
anti-TNF that caused psoriatic lesions in most of these
patients (69%); none of them had previous history of
psoriasis.92,93
The most frequent clinical presentation of psoriasis
occurring during TNF blockade is the palmoplantar type,
which differs from the classic plaque-type that occurs in
over 80% of psoriasis patients.63,66,91 Psoriatic lesions can
appear at any moment after drug initiation, but the most
frequent time of onset is between the 3rd and 4th IFX
infusion.66,68,84
In the majority of cases, psoriatic lesions resolved after
discontinuation of TNF blockers. In some patients who
Figure 3 Psoriatic lesion under infliximab therapy: Ear lobe.
773Anti-TNF and IBD: dermatological manifestationsshowed resolution of psoriasis after discontinuation of IFX,
skin lesions reappeared after the start of etanercept or
adalimumab.66,91,94
A prospective study on dermatological side effects under
adalimumab therapy in IBD patients shows 9 cases of eczema
and 9 cases of acne-like dermatitis: 6 of these patients
developed psoriatic lesions.95
The management of this paradoxical side effect is not
conclusive, and various treatment options have been employed
with mixed results. Biopsy should be considered in all patients
with new-onset psoriatic lesions. For mild skin lesions
responsive to topical therapy, it is reasonable to try continu-
ation of anti-TNF therapy. According to Collamer's algorithm,
patients with psoriasis covering b5% of body surface area
should be treated with topical treatments (corticosteroids,
keratolytics and vitamine D analogs); for lesions covering N5%
of body surface area and palmoplantar disease, topical
therapies, occlusive therapy to the palms and soles, and UV
phototherapy should be given.62
However, in the severe cases, treatment should include
both withdrawal of anti-TNF and consequent treatment of
psoriasis.63,91,96 In most cases, topical treatments such as
steroids, UVB-radiation and PUVA will be sufficient. In some
patients systemic treatment (metotrexate, fumaric acid,
other biologicals) will be necessary. Finally, the switch to
another anti-TNF agent can be considered in patients with a
general skin disease and/or aggressive IBD.
We show seven examples of psoriatic lesions manifested
under IFX treatment, in our centres (Figs. 2–8).
4.2. Cutaneous lupus and lupus-like syndrome
Biological agents have been reported to cause a drug-induced
lupus-like syndrome defined more specifically as TAILS (TNF
alpha antagonist-induced lupus-like syndrome).4,97 TAILS is a
rare condition with an incidence of less than 1% overall, and,
as a recent study on a Spanish cohort of 105 patients with
TAILS has confirmed, it occurs most often inwomen in the fifth
decade of life.98,99 TAILS has been observed in patients
treated with TNF blockers for various autoimmune diseases,
mostly RA and CD.98–103 IFX and etanercept are the two most
common biological agents associated with this syndrome. To
date, there are only a few cases of adalimumab-induced
lupus-like syndrome and one case of certolizumab-inducedFigure 2 Psoriatic lesion under infliximab therapy: Chin.lupus-like syndrome.98,100,102,103 It is likely that the increased
incidence of TAILS associatedwith IFX and etanercept is due to
the larger population that has been treated with these drugs.
Nevertheless, it has been shown that each anti-TNF agent has
particular structural and pharmacokinetic features that may
contribute to the different incidence rates of TAILS. Indeed,
IFX is the most immunogenic of the anti-TNF agents, due to
its chimeric structure. The fully humanised structure of
adalimumab is the least immunogenic. They have different
capacities to stimulate autoantibody production.
An aetiology has not been determined, and several
hypotheses have been proposed. Some investigators have
suggested that anti-TNF induced apoptosis of inflammato-
ry cells may release DNA and other lupus auto-antigens,Figure 4 Psoriatic lesion under infliximab therapy: Auricolar
region.
Figure 5 Psoriatic lesion under infliximab therapy: Scalp
psoriasis with alopecia.
Figure 7 Psoriatic lesion under infliximab therapy: Ungual
psoriasis.
774 G. Mocci et al.which may elicit the development of autoantibodies.104
However, this mechanism should not be implied in TAILS
caused by etanercept, as this agent does not cause cell
apoptosis. A second possible mechanism of pathogenesis
includes immune suppression that favours increased rates
of infection with the consequent activation of B lympho-
cytes and autoantibody production.105 Finally, a third
possible mechanism hypothesises that anti-TNF agents
may promote humoural autoimmunity by blocking T-helper
1 cells and favouring T-helper 2 immune responses.104,106
TAILS can appear in two different clinical variants. The
limited skin lupus type is characterised by cutaneous symptoms
of lupus (malar rash, photosensitive rash, purpura, alopecia)Figure 6 Psoriatic lesion under infliximab therapy: Right
arm.together with antinuclear antibodies (ANAs) and anti-dsDNA
autoantibody. The complete lupus type is characterised by
both autoantibodies and skin manifestations as well as
extra-cutaneous manifestations such as arthritis, myositis,
serositis, haematological abnormalities, and renal andFigure 8 Psoriatic lesion under infliximab therapy: Plantar
psoriasis.
775Anti-TNF and IBD: dermatological manifestationsneurological disorders.97–99,107,108 There are no differences
in terms of clinical presentation between the different TNF
agents. The time for onset of symptoms varies very much
(10 days to 54 months after start of therapy).98–100
It has been well documented that anti-TNF therapy is
associated with the induction of autoantibodies.101,109,110
New onset, positive ANAs have been reported in up to
two-thirds of previously negative-ANA patients treated with
TNF inhibitors. Anti-dsDNA was found in 70–90% of patients
treated with TNF inhibitors and was observed in 20% of IFX
patients. Notably, the majority of new anti-dsDNA anti-
bodies are of the IgM subtype; these are not more
pathogenic than the IgG subtype.4,15 Anti-phospholipid
antibodies have been found in 11–50% of patients.99,102 In
a prospective cohort study of 125 CD patients under IFX
therapy, a cumulative incidence of ANAs of 56.8% was found.
ANAs were associated with the female sex and skin
manifestations. In this cohort only 2 patients developed
drug-induced lupus erythematosus.111
Specific criteria for the diagnosis of TAILS have not been
established. The most rigorous criteria include the follow-
ing: a temporal relationship between clinical manifestations
and anti-TNF therapy, at least one of the serologic criteria
for systemic lupus erythematous according to the American
Congress of Rheumatology (ACR) (i.e., ANAs or anti-dsDNA),
and at least one non-serologic ACR criteria (i.e., arthritis,
serositis, malar rash, or hematologic disorder).100
The management of TAILS depends on the severity of
clinical presentation because TNF antagonists need to be
discontinued only in patients with organ involvement.
Moreover, patients with severe reactions may require
additional treatment, such as systemic or topical cortico-
steroids and immunosuppressives.108 In nearly all cases,
TAILS may be reversible, when the harmful drug is stopped,
within a period from three weeks to six months.98,100,109
Authors agree that the induction of autoantibodies in
asymptomatic patients is not an indication for the discon-
tinuation of therapy.4,108
An interesting question is whether patients with TAILS can
receive another anti-TNF agent without the recurrence of
adverse effects. Reports regarding this issue are scarce, and
there are only 10 patients that have been challenged with the
same or different agents to date.98,112,113 Adalimumab and
etanercept have been used with success, whereas, to our
knowledge, successful re-challenge has not been documented
with IFX. Interestingly, there are three cases of etanercept-
induced TAILS that tolerated re-challenge with the same
anti-TNF agent without recurrence.1134.3. Cutaneous vasculitis, erythema multiforme,
Stevens Johnson syndrome and
other cutaneous reactions
Ramos–Casals and colleagues conducted a baseline Medline
search of articles published between January 1990 and May
2008. They identified a total of 379 cases of autoimmune
diseases and other intolerance reactions; 118 cases of
cutaneous vasculitis were reported. However, these data are
sparse, due to a lack of biopsy data, and confounded by the
concomitant presence of RA (more than 80% of cases), which is
frequently associated with vasculitis. Purpura is the mostcommon presentation, and nearly all cases disappear when
anti-TNF therapy was discontinued.99 The management of
cutaneous vasculitis consists of evaluation for and treatment
of systemic involvement. Discontinuation of TNF blockademay
be suggested.
Safety reviews of TNF antagonists, including IFX, etanercept,
and adalimumab, identified rare cases of serious skin reactions,
including erythema multiforme (EM), Stevens–Johnson syn-
drome (SJS), and toxic epidermal necrolysis (TEN), associated
with the use of these biological products.114–116 Most affected
patients were female with rheumatoid arthritis, and nearly half
of the cases resulted in hospitalisations (22 of 50). Although
most had co-administration of one or more medications
associated with EM, SJS and/or TEN, several reports described
a temporal relationship between the start or most recent dose
of an anti-TNF agent and the onset of the skin reactions.
Moreover, more than half of the patients had a positive
de-challenge test.114
The development of any severe skin reactionwhile receiving
TNF antagonist therapy may require urgent work-up to
determine the appropriate diagnosis and treatment and to
guide consideration of an alternative therapy. IFX and other
anti-TNF agents must be stopped in cases of SJS or TEN.5. Skin cancers
Several case reports have documented that the use of TNF
inhibitors may be associated with an increased incidence of
non-melanoma skin cancer (NMSC), particularly squamous cell
carcinoma.7,10,15,30 A recent meta-analysis of randomised
controlled trials of adalimumab, IFX and etanercept demon-
strated that the relative risk associated with all anti-TNF
therapies for NMSCs was 2.02.117
In a cohort of 108,579 IBD patients, IBD was associated with
an increased incidence of melanoma and NMSC (IRR 1.29, IRR
1.46 respectively), especially for individuals with CD.118
Burmester et al. revised 71 global clinical trials including
23,458 patients exposed to adalimumab for different autoim-
mune disorders, and showed that standardised incidence rates
(SIRs) for NMCS were based on 22 events from CD trials (14
basal cell carcinoma, 6 squamous cell carcinoma and 2 not
classified). In CD, SIRs for melanomas did not show a higher
incidence relative to the general population.119 In a meta-
analysis of data from registries and systematic reviews about
patients with RA treated with anti-TNF, no evidence was
found that anti-TNF therapy exacerbated the risk of NMSC, but
this cannot be excluded.120
So, the responsibility of TNF in skin cancer remains
unclear, and data for actual rates of NMSCs are confounded
by other past or concomitant aetiologic factors.
Specifically, psoralen and ultraviolet A (PUVA), ultravio-
let B (UVB) and other immunosuppressive therapies, such as
cyclosporine, methotrexate or thiopurines, can influence
malignancy rates.7,10,30,121–125 Ongoing and past exposure to
thiopurines seems to significantly increase the risk of NMSC
in IBD patients even before the age of 50 years.126
All patients treated with anti-TNF should be protected
against UV radiation and receive a dermatologic examination
before starting therapy and then once a year thereafter.
Newly diagnosed NMSCs must be completely removed and
776 G. Mocci et al.followed, but anti-TNF agents do not necessarily have to be
discontinued.
6. Conclusion
Anti-TNF agents actually offer a significant improvement in
IBD. As a result of their use, and of the longer follow-up periods
of treatments, there are a growing number of cutaneous side
effects during anti-TNF treatment in IBD patients. These are
typically mild and are treated using standard topical therapies
without discontinuing or switching the anti-TNF agent. But in
the most severe cases, the discontinuation of the drug is
necessary. So, a close surveillance by a physician who deals
with IBD patients is very important and a consultation with a
dermatologist is highly recommended before and during
anti-TNF treatment.
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